Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05324982 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
A Phase 1 study of Behavioral Pharmacology of Cannabis, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05324982 is a Phase 1 study of Behavioral Pharmacology of Cannabis that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05324982, a Phase 1 study of Behavioral Pharmacology of Cannabis, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the cannabis plant formulated for oral consumption, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design.Upon enrollment, participants will complete 5 oral dosing conditions (placebo, 25, 50, 100, and 200 mg CBG). Each condition will consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute pharmacodynamic and pharmacokinetic drug effects. This work will provide novel data on the pharmacokinetics, pharmacodynamic effects, and safety of acute oral CBG dose administration in humans.
Conditions Studied
Interventions
- DRUG Oral Placebo
- DRUG Oral CBG Cannabis
Study Locations (1)
Maryland
- Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05324982
The ClinicalTrials.gov registry entry for NCT05324982 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Behavioral Pharmacology of Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Oral Placebo is the first listed.
NCT05324982 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05324982 about?
NCT05324982 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants". The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the cannabis plant formulated for oral consumption, in healthy adults. The study will utilize a within-subjects, placebo-controlled, ...
What is the current status of trial NCT05324982?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-08-09. Estimated completion is 2025-12.
What conditions does trial NCT05324982 study?
This clinical trial studies the following conditions: Behavioral Pharmacology of Cannabis.
What interventions are being tested in trial NCT05324982?
The interventions under investigation include: Oral Placebo (DRUG), Oral CBG Cannabis (DRUG).
Who is sponsoring clinical trial NCT05324982?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05324982 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.